Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2024-06-06 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
防止控股股东及其关联方资金占用管理办法（2024年6月）
Governance Information Classification · 95% confidence The document is titled as a management policy document regarding prevention of fund occupation by controlling shareholders and their related parties. It contains detailed internal rules, principles, responsibilities, and supervisory measures related to corporate governance and financial management. There are no financial statements, earnings data, or regulatory filings such as audit reports or annual reports. The document is a governance-related internal policy issued by the company's board, dated June 6, 2024. It does not announce or attach any report but sets out governance rules and procedures. Therefore, it fits best under Governance Information (CGR). The document length is 3085 characters, which is relatively short but contains substantive governance content rather than a mere announcement or certification.
2024-06-06 Chinese
监事会议事规则（2024年6月）
Governance Information Classification · 100% confidence The document is titled '监事会议事规则' which translates to 'Supervisory Board Meeting Rules' for 葵花药业集团股份有限公司. It details the rules, responsibilities, meeting procedures, and governance related to the supervisory board of the company. There are no financial statements, audit opinions, or financial results presented. The document is a governance-related internal rules document, focusing on the structure and operation of the supervisory board, referencing relevant laws and regulations. It is not an announcement, report, or presentation of financial or operational results. Therefore, the document fits best under Governance Information (CGR). The document length is 4437 characters, which is sufficient for a detailed governance document but too short for a full annual or interim report. No indication of voting results, capital changes, or other categories is present.
2024-06-06 Chinese
关于购买董监高责任险的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the purchase of directors and officers liability insurance (董监高责任险) by the company 葵花药业集团股份有限公司. It details the insurance plan, the approval process by the board and supervisory committee, and the submission of the matter to the shareholders' meeting for approval. The document is a formal announcement of a corporate governance-related matter, specifically about board and management insurance arrangements. It does not contain financial statements, earnings data, or detailed management discussion. It is not a report or presentation but an announcement of a corporate governance decision requiring shareholder approval. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions related to the company's board or senior management.
2024-06-06 Chinese
对外投资管理办法（2024年6月）
Governance Information Classification · 95% confidence The document is titled '葵花药业集团股份有限公司 对外投资管理办法' which translates to 'External Investment Management Measures of Kuaihua Pharmaceutical Group Co., Ltd.' It is a detailed internal policy document outlining the principles, decision-making authority, responsibilities, execution control, disposal, supervision, and disclosure related to the company's external investments. It includes references to compliance with laws and regulations, internal controls, and governance procedures. There is no indication that this is a financial report, earnings release, audit report, or any form of regulatory filing. It is a governance-related internal control document focused on investment management policies. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 4565 characters, which is substantive and not a brief announcement or certification, supporting this classification.
2024-06-06 Chinese
对外提供财务资助管理制度（2024年6月）
Governance Information Classification · 95% confidence The document is titled as a management system or policy document regarding the company's external financial assistance management system. It outlines rules, procedures, and governance related to providing financial support to external parties, including approval processes, disclosure obligations, and risk management. There are no financial statements, earnings data, or report summaries present. The document is a governance or internal control policy rather than a financial report or announcement. It is not an announcement of a report publication, nor a certification or legal proceeding. The content fits best under Governance Information (CGR) as it details internal rules and governance practices related to financial assistance.
2024-06-06 Chinese
关于调整独立董事薪酬（津贴）的公告
Remuneration Information Classification · 100% confidence The document is an announcement regarding the adjustment of independent directors' remuneration (salary/allowance) by the company 葵花药业集团股份有限公司. It details the proposed remuneration scheme, the approval process by the board and the need for shareholder meeting approval. There is no financial data, no report attached or referenced as being published, and the document focuses on board-related compensation changes. This fits the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2024-06-06 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.